Insulet (PODD)

• Market cap: $19.8B
• 1 day: -1.90%
• 5 days: 0.40%
• 1 month: 2.43%
• 3 months: 7.94%
• 6 months: 52.21%
• Year to date: 10.10%
• 1 year: 46.92%
• 5 years: 33.20%
• 10 years: 782.10%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Employees: 3,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

150% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]

135% more first-time investments, than exits

New positions opened: 115 | Existing positions closed: 49

12% more capital invested

Capital invested by funds: $16.4B [Q3] → $18.3B (+$1.97B) [Q4]

7% more funds holding

Funds holding: 610 [Q3] → 652 (+42) [Q4]

6% more repeat investments, than reductions

Existing positions increased: 235 | Existing positions reduced: 221

0.65% less ownership

Funds ownership: 100.72% [Q3] → 100.08% (-0.65%) [Q4]

31% less call options, than puts

Call options by funds: $123M | Put options by funds: $177M

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $293 4% upside
• Avg. target: $321 14% upside
• High target: $355 26% upside

9 analyst ratings

• positive: 8 89%
• neutral: 1 11%
• negative: 0 0%

Citigroup Joanne Wuensch 73% 1-year accuracy 35 / 48 met price target	26% upside $355	Buy Maintained	21 Feb 2025
Raymond James Jayson Bedford 80% 1-year accuracy 20 / 25 met price target	16% upside $328	Outperform Reiterated	21 Feb 2025
Stifel Mathew Blackman 53% 1-year accuracy 9 / 17 met price target	4% upside $293	Hold Maintained	21 Feb 2025
Piper Sandler Matt O'Brien 64% 1-year accuracy 35 / 55 met price target	10% upside $310	Overweight Maintained	21 Feb 2025
Wells Fargo Lawrence Biegelsen 75% 1-year accuracy 3 / 4 met price target	14% upside $322	Overweight Maintained	21 Feb 2025